They further recommend testing for specific gene fusions, RAS/RAS driver mutations, homologous repair (BRCA1, BRCA2, PALB2) and mismatch repair mutations (MLH1, MSH2, MSH6, PMS2), as well as tumor microsatellite instability and tumor mutational burden. The gene discussed is BRCA2; the disease is neoplasm.